Zatolmilast is a Small Molecule owned by Tetra Therapeutics, and is involved in 11 clinical trials, of which 7 were completed, and 4 are ongoing.
BPN-14770 elicit therapeutic intervention by acting as inhibitor to phosphodiesterase 4 (PDE 4D). Phosphodiesterase 4D is the subtype of enzyme PDE4 which breaks down cAMP, an important neuronal and intracellular signaling molecule. The drug candidate by blocking PDE4 activity activates the protein kinase A which phosphorylates and activates the subsequent downstream target cAMP-response element binding (CREB) protein. This signalling cascade by enhancing the memory improves cognitive functions and disease condition.
The revenue for Zatolmilast is expected to reach a total of $496m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zatolmilast NPV Report.
Zatolmilast is originated and owned by Tetra Therapeutics. Shionogi & is the other company associated in development or marketing of Zatolmilast.
BPN-14770 is under development for the treatment of fragile X syndrome, traumatic brain injury and Alzheimer's disease. The drug candidate is administered through oral route. It acts by targeting enzyme phosphodiesterase 4 (PDE 4D) enzyme.
Shionogi & Overview
Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.
Quick View – Zatolmilast
|Highest Development Stage|